Myeloma 2017 -  Year in Review with MMRF

Myeloma 2017 - Year in Review with MMRF

The MMRF is pioneering precision medicine initiatives in multiple myeloma. This would help match patients to the most effective therapies based on their genetics and other unique factors. We are talking to Anne Quinn Young of MMRF to review myeloma research initiatives at The MMRF, specifically cover The MMRF CoMMPass Study updates, MMRF Answer Fund program, clinical trials currently recruiting and opportunities that patients can explore to share their data and participate in research efforts to accelerate precision medicine.


Talk Recorded on Jan. 25, 2018, 1 p.m. EST </> Embed

Hear Talk Audio

  • Anonymous User March 1, 2018, 2:57 p.m.  US/Eastern

    Is this precision method just for newly diagnosed patients or ones who have had one or two different treatments over a few years?

  • Anonymous User Jan. 25, 2018, 4:07 p.m.  US/Eastern

    Question for Anne: I am an MM patient and also a data scientist. I am interested in accessing the MMRF Compass data for analysis. I applied at the MMRF site for access and haven't heard back. How can I get access?

  • Anonymous User Jan. 25, 2018, 1:57 p.m.  US/Eastern

    I have a background in big data analytics. If I'm interested in participating in the upcoming Answer Fund program, how would I get information and get started?

  • Anonymous User Jan. 25, 2018, 9:23 a.m.  US/Eastern

    With this accelerated pace of development, the precision medicine initiative and other programs that MMRF is leading, do you predict a tentative timeline by which we can expect to see myeloma “cure”?

  • Anonymous User Jan. 25, 2018, 9:05 a.m.  US/Eastern

    What advancements can we expect to happen this year, in high risk myeloma management?